See more : Denali Bancorporation, Inc. (DENI) Income Statement Analysis – Financial Results
Complete financial analysis of Puma Biotechnology, Inc. (PBYI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Puma Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- JFLA Holdings Inc. (3069.T) Income Statement Analysis – Financial Results
- Sonoma Pharmaceuticals, Inc. (SNOA) Income Statement Analysis – Financial Results
- MEI Pharma, Inc. (MEIP) Income Statement Analysis – Financial Results
- Niyogin Fintech Limited (NIYOGIN.BO) Income Statement Analysis – Financial Results
- Zenken Corporation (7371.T) Income Statement Analysis – Financial Results
Puma Biotechnology, Inc. (PBYI)
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 235.64M | 228.00M | 253.20M | 225.10M | 272.30M | 251.00M | 27.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -281.10K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 62.68M | 55.10M | 63.70M | 39.40M | 36.80M | 34.60M | 5.60M | 1.15M | 776.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 172.96M | 172.90M | 189.50M | 185.70M | 235.50M | 216.40M | 22.10M | -1.15M | -776.00K | 0.00 | 0.00 | 0.00 | -281.10K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 73.40% | 75.83% | 74.84% | 82.50% | 86.49% | 86.22% | 79.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 50.38M | 52.20M | 71.90M | 97.70M | 132.90M | 164.90M | 207.80M | 222.80M | 208.50M | 122.90M | 45.05M | 49.60M | 826.37K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 88.43M | 89.98M | 116.29M | 118.49M | 140.51M | 146.19M | 106.70M | 53.80M | 31.80M | 19.40M | 9.79M | 24.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 881.00K | 22.00K | 6.00K | -88.00K | 1.19M | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 89.31M | 90.00M | 116.30M | 118.40M | 141.70M | 146.20M | 106.70M | 53.80M | 31.80M | 19.40M | 9.79M | 24.80M | 9.32M | 15.98K | 16.84K | 14.08K | 0.00 |
| Other Expenses | 625.00K | -28.00K | 300.00K | 400.00K | 200.00K | -9.70M | -100.00K | -400.00K | 25.00K | -14.00K | 2.00K | 293.00K | 10.70K | 0.00 | 0.00 | 0.00 | -15.09M |
| Operating Expenses | 140.32M | 142.20M | 188.20M | 216.10M | 274.60M | 311.10M | 314.50M | 276.60M | 240.30M | 142.30M | 54.83M | 74.40M | 10.16M | 15.98K | 16.84K | 14.08K | -15.09M |
| Cost & Expenses | 203.00M | 197.30M | 251.90M | 255.50M | 311.40M | 345.70M | 320.10M | 276.60M | 240.30M | 142.30M | 54.83M | 74.40M | 10.16M | 15.98K | 16.84K | 14.08K | -15.09M |
| Interest Income | 2.61M | 800.00K | 100.00K | 500.00K | 2.80M | 1.80M | 1.20M | 1.00M | 1.00M | 300.00K | 172.00K | 100.00K | 3.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.33M | 11.50M | 12.80M | 14.10M | 15.00M | 11.00M | 700.00K | 958.00K | 971.00K | 324.00K | 172.00K | 98.00K | 3.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.52M | 8.92M | 10.60M | 7.20M | 4.80M | 7.38M | 2.81M | 1.15M | 776.00K | 627.00K | 423.00K | 265.00K | 10.70K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 47.52M | 20.97M | -5.40M | -38.54M | -55.72M | -95.21M | -288.42M | -275.45M | -239.50M | -141.65M | -54.41M | -74.09M | -10.22M | -15.98K | -16.84K | -14.08K | -15.09M |
| EBITDA Ratio | 20.17% | 13.82% | 0.67% | -13.11% | -13.26% | -40.88% | -1,051.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,580.97% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 32.64M | 23.70M | -8.90M | -30.40M | -39.10M | -94.70M | -292.40M | -276.60M | -240.30M | -142.30M | -54.83M | -74.40M | -10.16M | -15.98K | -16.84K | -14.08K | -15.09M |
| Operating Income Ratio | 13.85% | 10.39% | -3.51% | -13.51% | -14.36% | -37.73% | -1,055.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,613.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -9.97M | -23.26M | -30.09M | -29.39M | 53.00K | -18.92M | 435.00K | 585.00K | 996.00K | 310.00K | 174.00K | 98.00K | -76.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 22.67M | 500.00K | -28.80M | -59.80M | -75.60M | -113.60M | -292.00M | -276.00M | -239.30M | -142.00M | -54.66M | -74.30M | -10.23M | -15.98K | -16.84K | -14.08K | -15.09M |
| Income Before Tax Ratio | 9.62% | 0.22% | -11.37% | -26.57% | -27.76% | -45.26% | -1,054.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,640.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.08M | 500.00K | 300.00K | 200.00K | 7.12M | -7.92M | -2.21M | -2.15M | -1.75M | -941.00K | -172.00K | -267.00K | 76.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 21.59M | 912.00K | -29.10M | -60.00M | -82.72M | -113.60M | -292.00M | -276.00M | -239.30M | -142.00M | -54.66M | -74.30M | -10.23M | -15.98K | -16.84K | -14.08K | -15.09M |
| Net Income Ratio | 9.16% | 0.40% | -11.49% | -26.65% | -30.38% | -45.26% | -1,054.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,640.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.46 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | -7.86 | -8.29 | -7.45 | -4.73 | -1.90 | -3.42 | -0.51 | 0.00 | -0.01 | 0.00 | -0.38 |
| EPS Diluted | 0.45 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | -7.86 | -8.29 | -7.45 | -4.73 | -1.90 | -3.42 | -0.51 | 0.00 | -0.01 | 0.00 | -0.38 |
| Weighted Avg Shares Out | 47.13M | 44.67M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M | 32.13M | 30.01M | 28.70M | 21.73M | 20.04M | 7.75M | 3.00M | 3.00M | 39.29M |
| Weighted Avg Shares Out (Dil) | 47.55M | 44.93M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M | 32.13M | 30.01M | 28.70M | 21.73M | 20.04M | 7.75M | 3.00M | 3.00M | 39.29M |
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue operating results for 2Q-2023 on Aug. 3 and follow with a conference call at 1:30 pm PT.
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Genmab A/S Sponsored ADR (GMAB). But which of these two stocks is more attractive to value investors?
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2023, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 22,500 shares of Puma common stock...
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Biomarker findings from a P II study of alisertib+paclitaxel v. paclitaxel alone in met. HR+ and triple neg breast cancer were presented at ASCO 2023.
PBYI or TECH: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Techne (TECH). But which of these two companies is the best option for those looking for undervalued stocks?
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.
PBYI vs. TECH: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Puma Biotech (PBYI) or Techne (TECH). But which of these two companies is the best option for those looking for undervalued stocks?
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y
Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.
Puma Biotechnology, Inc. (PBYI) Q1 2023 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chairman, President and CEO Maximo Nougues - Chief Financial Officer Jeff Ludwig...
Source: https://incomestatements.info
Category: Stock Reports